Prospective Investigation of the New Coronavirus and Antiviral Drugs with Potential Therapeutic Activity for the Treatment of Infected Patients by COVID-19
DOI:
https://doi.org/10.9771/cp.v13i3.36384Keywords:
Coronavirus, COVID-19 , Treatment, Drugs.Abstract
The COVID-19 pandemy, caused by a new coronavirus found in December 2019 in Wuhan, China, has infected 754,498 people and promoted the death of 36,571 people worldwide until March 31, 2020. Almost all the countries experimented collapses in them health system to take care of their population. This paper is devoted to show a scientific and technological mapping about this new virus and antiviral drugs with potential therapeutic activities in the treatment of COVID-19, it was performed by analysis of scientific papers and patents from Brazilian and international databases. 2,977 patents (Orbit) and 14,056 articles (Scopus) were found about coronavirus and 296 articles (Scopus) specifically about the new coronavirus, predominantly from China. More than 20 antiviral drugs were identified and are under evaluation in different parts of the world. The results also brings some news about the actual potential of use of some drugs like chloroquine, hydroxychloroquine, Ritonavir, Lopinavir, Remdesivir and Ribavirin.
Downloads
References
AMIRIAN, E. Susan; LEVY, Julie K. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health, [S.l.], p. 100128, 2020.
CAI, Qingxian et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering, [S.l.], 2020.
CUI, J.; LI, F.; SHI, Z.L. Shi. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol., [S.l.], n. 17, p. 181-192, 2019.
DERWENT. Base de dados on-line. [2020]. Disponível em: http://apps-webofknowledge.ez9.periodicos.capes.gov.br/DIIDW_GeneralSearch_input.do?product=DIIDW&SID=7Ar5bU9PQIZ4iN71VS3&search_mode=GeneralSearch. Acesso em: 30 mar. 2020.
DROSTEN, Christian et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England Journal of Medicine, [S.l.], v. 348, n. 20, p. 1.967-1.976, 2003.
ELFIKY, Abdo A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, [S.l.], p. 117592, 2020.
ESPACENET. Base de dados on-line. [2020]. Disponível em: https://worldwide.espacenet.com/. Acesso em: 30 mar. 2020.
FAVALLI, Ennio Giulio et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmunity Reviews, [S.l.], p. 102523, 2020.
FOSTER, S.; TYLER, V. E. Tyler's Honest Herbal, 4th ed. Binghamton, NY: Haworth Herbal Press, 1999, 442 p.
GILBERT, Marius et al. Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. The Lancet, [S.l.], v. 395, n. 10.227, p. 871-877, 2020.
GUPTA, Ritesh; MISRA, Anoop. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc.). Diabetes & Metabolic Syndrome: Clinical Research & Reviews, [S.l.], 2020.
HAN, Qingmei et al. Coronavirus 2019-nCoV: A brief perspective from the front line. Journal of Infection, [S.l.], v. 80, n. 4, p. 373-377, 2020.
INPI – INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL. Base de dados on-line. [2020]. Disponível em: https://gru.inpi.gov.br/pePI/jsp/patentes/PatenteSearchAvancado.jsp. Acesso em: 30 mar. 2020.
INPI – INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL. Classificação de patentes. 2020. Disponível em: http://www.inpi.gov.br/menu-servicos/patente/classificacao-de-patentes. Acesso em: 30 mar. 2020.
KHACHFE, Hussein H. et al. An epidemiological study on COVID-19: a rapidly spreading disease. Cureus, [S.l.], v. 12, n. 3, 2020.
KSIAZEK, Thomas G. et al. A novel coronavirus associated with severe acute respiratory syndrome. New England Journal of Medicine, [S.l.], v. 348, n. 20, p. 1.953-1.966, 2003.
LI, Heng et al. Coronavirus disease 2019 (COVID-19): current status and future perspective. International Journal of Antimicrobial Agents, [S.l.], p. 105951, 2020.
LI, Jin-Yan et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes and Infection, [S.l.], v. 22, n. 2, p. 80-85, 2020.
LI, Xiaowei et al. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis, [S.l.], 2020.
PEERI, Noah C. et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? International Journal of Epidemiology, [S.l.], 2020.
QUESTEL ORBIT. Base de dados on-line. [2020]. Disponível em: https://www.orbit.com. Acesso em: 30 mar. 2020.
ROTHAN, Hussin A.; BYRAREDDY, Siddappa N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity, [S.l.], p. 102433, 2020.
SCIENCE DIRECT. Base de dados on-line. [2020]. Disponível em: https://www.sciencedirect.com/. Acesso em: 30 mar. 2020.
SCIENTIFIC ELECTRONIC LIBRARY ONLINE (SciELO). Base de dados on-line. [2020]. Disponível em: http://www.scielo.org/php/index.php. Acesso em: 30 mar. 2020.
SCOPUS. Base de dados on-line. [2020]. Disponível em: https://www.scopus.com/home.uri. Acesso em: 30 mar. 2020.
SHEREEN, Muhammad Adnan et al. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research, [S.l.], 2020.
SIGMA-ALDRICH. Catálogo de produtos Químicos finos. [2020]. Disponível em: https://www.sigmaaldrich.com/catalog/product/aldrich/134910?lang=pt®ion=BR. Acesso em: 31 mar. 2020.
SINGH, Awadhesh Kumar et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, [S.l.], 2020.
TOURET, Franck; DE LAMBALLERIE, Xavier. Of chloroquine and COVID-19. Antiviral Research, [S.l.], p. 104762, 2020.
UNLUGENC, Hakki et al. Rapid fluid administration and the incidence of hypotension induced by spinal anesthesia and ephedrine requirement: the effect of crystalloid versus colloid coloading. Middle East J Anaesthesiol, [S.l.], v. 23, n. 3, p. 273-81, 2015.
WANG, Li-sheng et al. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. International Journal of Antimicrobial Agents, [S.l.], p. 105948, 2020.
WEB OF SICENCE. Base de dados on-line. [2020]. Disponível em: http://apps-webofknowledge.ez9.periodicos.capes.gov.br/WOS_GeneralSearch_input.do?product=WOS&search_mode=GeneralSearch&SID=7Ar5bU9PQIZ4iN71VS3&preferencesSaved=. Acesso em: 30 mar. 2020.
WEISS, Susan R.; LEIBOWITZ, Julian L. Coronavirus pathogenesis. In: WEISS, Susan R.; LEIBOWITZ, Julian L. Advances in Virus Research. [S.l.]: Academic Press, 2011. p. 85-164.
WHO – WORLD HEALTH ORGANIZATION. [2020]. Disponível em: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200331-sitrep-71-covid-19.pdf?sfvrsn=4360e92b_8. Acesso em: 31 mar. 2020.
WOO, Patrick Cy et al. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. Journal of Virology, [S.l.], v. 86, n. 7, p. 3.995-4.008, 2012.
ZHAI, Pan et al. The epidemiology, diagnosis and treatment of COVID-19. International Journal of Antimicrobial Agents, [S.l.], p. 105955, 2020.
ZHANG, Wen et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. Clinical Immunology, [S.l.], p. 108393, 2020.
ZHU, Na et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, [S.l.], 2020.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Cadernos de Prospecção
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
O autor declara que: - Todos os autores foram nomeados. - Está submetendo o manuscrito com o consentimento dos outros autores. - Caso o trabalho submetido tiver sido contratado por algum empregador, tem o consentimento do referido empregador. - Os autores estão cientes de que é condição de publicação que os manuscritos submetidos a esta revista não tenham sido publicados anteriormente e não sejam submetidos ou publicados simultaneamente em outro periódico sem prévia autorização do Conselho Editorial. - Os autores concordam que o seu artigo ou parte dele possa ser distribuído e/ou reproduzido por qualquer forma, incluindo traduções, desde que sejam citados de modo completo esta revista e os autores do manuscrito. - Revista Cadernos de Prospecção está licenciado com uma Licença Creative Commons Attribution 4.0. Esta licença permite que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, e embora os novos trabalhos tenham de lhe atribuir o devido crédito e não possam ser usados para fins comerciais, os usuários não têm de licenciar esses trabalhos derivados sob os mesmos termos.
Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.
